1. Changes in the Expression Profile of VEGF-A, VEGF-B, VEGFR-1, VEGFR-2 in Different Grades of Endometrial Cancer
   Konrad Dziobek et al, 2019, Current Pharmaceutical Biotechnology CrossRef
2. Interplay between miRNAs and Genes Associated with Cell Proliferation in Endometrial Cancer
   Ewelina Hermyt et al, 2019, International Journal of Molecular Sciences CrossRef
3. The influence of adalimumab on the expression profile of mRNAs and miRNAs related to the IL‐12 and IL‐23 signal paths
   D. Wcisło‐Dziadecka et al, 2019, Journal of the European Academy of Dermatology and Venereology CrossRef
4. Tumoral programmed cell death 1 (PD1) expression in endometrial carcinoma is a prognostic marker for patient outcome
   Barin Feroz et al, 2024, International Journal of Gynecologic Cancer CrossRef
5. Expression of NRP-1 and NRP-2 in Endometrial Cancer
   Marcin Oplawski et al, 2019, Current Pharmaceutical Biotechnology CrossRef
6. Variances in the Level of COX-2 and iNOS in Different Grades of Endometrial Cancer
   Marcin Oplawski et al, 2020, Current Pharmaceutical Biotechnology CrossRef
7. Assessment of Expression of Homeobox A5 in Endometrial Cancer on the mRNA and Protein Level
   Konrad Dziobek et al, 2020, Current Pharmaceutical Biotechnology CrossRef
8. Evaluation of Changes in the Expression Pattern of EDIL3 in Different Grades of Endometrial Cancer
   Marcin Oplawski et al, 2019, Current Pharmaceutical Biotechnology CrossRef
9. Assessment of the Usefulness of the SEMA5A Concentration Profile Changes as a Molecular Marker in Endometrial Cancer
   Konrad Dziobek et al, 2020, Current Pharmaceutical Biotechnology CrossRef
10. Changes in Expression Pattern of SEMA3F Depending on Endometrial Cancer Grade - Pilot Study
    Konrad Dziobek et al, 2019, Current Pharmaceutical Biotechnology CrossRef
11. Expression Profile of VEGF-C, VEGF-D, and VEGFR-3 in Different Grades of Endometrial Cancer
    Marcin Oplawski et al, 2019, Current Pharmaceutical Biotechnology CrossRef